Autophagy-associated immune responses and cancer immunotherapy

Hongming Pan; Liuxi Chen; Yinghua Xu; Weidong Han; Fang Lou; Weiqiang Fei; Shuiping Liu; Zhao Jing; Xinbing Sui

doi:10.18632/oncotarget.6908

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Autophagy-associated immune responses and cancer immunotherapy

Hongming Pan, Liuxi Chen, Yinghua Xu, Weidong Han, Fang Lou, Weiqiang Fei, Shuiping Liu, Zhao Jing and Xinbing Sui _

PDF | HTML | How to cite

Oncotarget. 2016; 7:21235-21246. https://doi.org/10.18632/oncotarget.6908

Metrics: PDF 3940 views | HTML 4400 views | ?

Abstract

Hongming Pan1,2,*, Liuxi Chen1,2,*, Yinghua Xu1,2, Weidong Han1,2, Fang Lou1,2, Weiqiang Fei2, Shuiping Liu2, Zhao Jing2 and Xinbing Sui1,2

1 Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China

2 Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, China

* These authors have contributed equally to this work

Correspondence to:

Xinbing Sui, email:

Keywords: autophagy, immune, cancer immunotherapy

Received: September 16, 2015 Accepted: January 06, 2016 Published: January 13, 2016

Abstract

Autophagy is an evolutionarily conserved catabolic process by which cellular components are sequestered into a double-membrane vesicle and delivered to the lysosome for terminal degradation and recycling. Accumulating evidence suggests that autophagy plays a critical role in cell survival, senescence and homeostasis, and its dysregulation is associated with a variety of diseases including cancer, cardiovascular disease, neurodegeneration. Recent studies show that autophagy is also an important regulator of cell immune response. However, the mechanism by which autophagy regulates tumor immune responses remains elusive. In this review, we will describe the role of autophagy in immune regulation and summarize the possible molecular mechanisms that are currently well documented in the ability of autophagy to control cell immune response. In addition, the scientific and clinical hurdles regarding the potential role of autophagy in cancer immunotherapy will be discussed.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6908

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Autophagy-associated immune responses and cancer immunotherapy

Abstract